Achieve Life Sciences Announces Exclusive Manufacturing Agreement

Pharmaceutical Investing

Achieve Life Sciences announced an exclusive supply agreement with Sopharma AD for the manufacture of cytisine active pharmaceutical ingredient and finished tablets.

Achieve Life Sciences (NASDAQ:ACHV) announced an exclusive supply agreement with Sopharma AD for the manufacture of cytisine active pharmaceutical ingredient and finished tablets.
As quoted in the press release:

Under the terms of the agreement, Sopharma agrees to produce cGMP-grade cytisine for Achieve’s use in the development and commercialization of cytisine. Sopharma has over 20 years of experience producing cytisine through its commercialization efforts in Central and Eastern Europe. In addition, Achieve will have full access to the cytisine supply chain and Sopharma will manufacture sufficient cytisine to meet specified forecasted demand of cytisine in the Achieve territories. The exclusive license agreement provides supply of cytisine to Achieve for up to 20 years.
“This agreement with Sopharma reinforces our commitment and ability to bring cytisine forward as a new treatment option to help the millions of smokers who are battling nicotine and tobacco addiction,” said Rick Stewart, Chairman and CEO of Achieve.

Click here to read the full press release.

Source: www.newswire.ca

The Conversation (0)
×